Découvrez nos professeurs et professeures!

Louis Lacombe

Directeur de département

Louis Lacombe
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Immunologie-infectiologie
Oncologie

Domaines et intérêts de recherche du (de la) professeur(e) :

Cancer
  • Cancer de l'appareil urinaire
  • Tabagisme et cancer
  • Environnement et cancer
  • Cancer la prostate
  • Carcinogénèse
  • Diagnostic et détection du cancer
  • Apoptose et cancer
  • Cancers hormonaux-dépendants
Génétique humaine
  • Interactions gènes et environnement
  • Gènes de susceptibilité

Projets de recherche

  • A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma - Merck Canada Inc., chercheur principal - 2023-09-22 au 2028-12-25
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy - Instituts de recherche en santé du Canada - Subvention Projet, co-chercheur - 2021-10-01 au 2026-09-30
  • UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER - Société de recherche sur le cancer - Subvention de fonctionnement, co-chercheur - 2023-09-01 au 2025-08-31
  • Aberrant UGT2828 androgne inactivation pathway predict prostate cancer progression. - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2022-02-05 au 2025-03-30
  • Soutien à la recherche - Université Laval - Fonds internes, chercheur principal - 2017-07-01 au 2024-06-30
  • Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression - Société de recherche sur le cancer - Subvention de fonctionnement, co-chercheur - 2021-09-01 au 2023-08-31
  • The Contribution of Non-Classical 11-oxy Androgens to Prostate Cancer Progression - Cancer de la prostate Canada - Subvention de découverte, co-chercheur - 2019-04-01 au 2022-03-30

Publications

  • Analysis of p21WAF1/CIP1 in primary bladder tumors., Cordon-Cardo C, Reuter VE, Fair WR, Gerald WL, Silver D, Orlow I, Lacombe L, Oncology research, 1996
  • Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy., Fradet Y, Moore L, Veilleux C, Meyer F, Maillette A, Lacombe L, International journal of cancer, 2001, 10.1002/1097-0215(20010520)95:3<135::aid-ijc1023>3.0.co;2-3
  • Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure., Fradet Y, Têtu B, Lacombe L, Bairati I, Moore L, Meyer F, The Journal of urology, 1999, 10.1016/s0022-5347(05)68092-5
  • Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors., Fradet Y, Meyer F, Têtu B, Larue H, Moore L, Vezina MC, Lacombe L, Pfister C, Human pathology, 1999, 10.1016/s0046-8177(99)90067-9
  • Male urethral carcinoma: analysis of treatment outcome., Herr HW, Lacombe L, Zhang ZF, Dalbagni G, Urology, 1999, 10.1016/s0090-4295(98)00659-1
  • Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis?, Fradet Y, Lacombe L, Naud A, Liandier F, Grégoire M, The Journal of urology, 2002, 10.1016/s0022-5347(05)64678-2
  • Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer., Fradet Y, Têtu B, Lacombe L, Bédard C, Bairati I, Meyer F, Urology, 2001, 10.1016/s0090-4295(01)01245-6
  • Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer., Fradet Y, Lacombe L, Bairati I, Têtu B, Meyer F, The Canadian journal of urology, 2006
  • Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study., CONFIDENCE Investigators, Yang K, Anand S, Tsoukas G, American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011, 10.2165/11587000-000000000-00000
  • Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy., Fradet Y, Lacombe L, Larue H, Laverdiere J, Latulippe E, Hovington H, Decobert M, Tiguert R, Rigaud J, The Prostate, 2004, 10.1002/pros.10329
  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy., Meyerson M, Cancer Genome Atlas Research Network, Lazar AJ, Liu J, Hu H, Wang C, Schumacher SE, Berger AC, Zhang X, Gao GF, Ha G, Shih J, Taylor AM, Cancer cell, 2018, 10.1016/j.ccell.2018.03.007
  • Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images., Thorsson V, Cancer Genome Atlas Research Network, Van Arnam J, Batiste R, Zhao T, Shroyer KR, Samaras D, Nguyen V, Singh P, Kurc T, Hou L, Gupta R, Saltz J, Cell reports, 2018, 10.1016/j.celrep.2018.03.086
  • lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer., Yang D, Xie W, Cancer Genome Atlas Research Network, Li S, Jia L, Wang Y, Wu Z, Guo W, Zhang M, Yang B, Wang Z, Cancer cell, 2018, 10.1016/j.ccell.2018.03.006
  • Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration., Pouliot F, Beauregard JM, Fradet Y, Makao-Nguile M, Fradet V, Lacombe L, Tiguert R, Dujardin T, Duchesnay N, Blouin AC, Buteau FA, Bergeron M, Lavallée E, European urology focus, 2018, 10.1016/j.euf.2018.03.008
  • Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas., Cancer Genome Atlas Network, Eisenman RN, Cherniack AD, Hurlin PJ, Ayer DE, Liu Y, Ventura A, Zhang X, Zhao W, Shaw R, Richardson AB, Trivedi M, Berger AC, Dhankani V, Schaub FX, Cell systems, 2018, 10.1016/j.cels.2018.03.003
  • Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review., Fradet V, Lacombe L, Fradet Y, Robitaille K, Lamarche B, Ben-Zvi T, Allaire J, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4471
  • PROGRAMME SCIENTIFIQUE : Samedi, le 15 novembre 2008, Session scientifique VIII, Aprikian A, Chevallier S, Bladou F, Rocchi P, Andrieu C, Karsenty G, Cury J, Aprikian A, Steinberg J, Tanguay S, Kassouf W, Jeyaganth S, Amin M, Fahmy N, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • PROGRAMME SCIENTIFIQUE : Vendredi, le 14 novembre 2008, Session scientifique V, Fradet Y, Asker A, Letendre J, Jeldres C, Baillargeon-Gagné S, Fradet Y, Lacombe L, Larue H, Harel F, Hovington H, Lessard A, Blackburn F, Moore K, Aziz A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy., Fradet Y, Lacombe L, Têtu B, Bergeron A, Harel F, Decobert M, Hovington H, LaRue H, Ayari C, European urology, 2009, 10.1016/j.eururo.2009.01.040
  • Denosumab in men receiving androgen-deprivation therapy for prostate cancer., Denosumab HALT Prostate Cancer Study Group, Goessl C, Leder BZ, Kupic A, Ke C, Szwedowski M, Heracek J, Saad F, Tammela TL, Feldman R, Hernández Toriz N, Egerdie B, Smith MR, The New England journal of medicine, 2009, 10.1056/nejmoa0809003
  • Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database., Estey EP, Lattouf JB, Drachenberg DE, Cagiannos I, Bell D, Rendon RA, Lacombe L, Fradet Y, Izawa JI, Chin JL, Aprikian AG, Kassouf W, Fairey AS, Urologic oncology, 2011, 10.1016/j.urolonc.2011.07.014
  • Abstraits AUQ 2013, Haddad R, Aharony S, Sun M, Karakiewicz P, Trinh Q, Perrotte P, Tian Z, Gandaglia G, Abdo A, Hanna N, Kluth L, Shariat S, Roghmann F, Becker A, Trudeau V, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013
  • Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy., Fradet Y, Mian M, Puppo P, Naselli A, Lacombe L, Lodde M, World journal of urology, 2012, 10.1007/s00345-012-0827-z
  • Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome., Kassouf W, Saad F, Fradet Y, Bell D, Lattouf JB, So A, Chin J, Lacombe L, Black P, Kapoor A, Izawa J, Fairey A, Jacobsen N, Rendon R, Tanguay S, Yafi FA, Urologic oncology, 2013, 10.1016/j.urolonc.2012.11.014
  • Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank., Chevalier S, Carmel M, Lacombe L, Saad F, McKercher G, Hamel L, Scarlata E, Doueik A, Têtu B, Latour M, Aprikian A, Brimo F, Biopreservation and biobanking, 2013, 10.1089/bio.2013.0025
  • Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma., Kassouf W, Saad F, Lattouf JB, So A, Black P, Matsumoto E, Kapoor A, Chin J, Izawa J, Bell D, Rendon R, Tanguay S, Estey E, Jacobsen NE, Fairey AS, European urology, 2013, 10.1016/j.eururo.2013.06.014
  • Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer., Kassouf W, Drachenberg D, Bell D, Saad F, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin JL, Aprikian AG, Yafi FA, World journal of urology, 2013, 10.1007/s00345-013-1207-z
  • Complete Penile Necrosis in a Patient With Heparin-induced Thrombocytopenia: A Case Report., Lacombe L, Deschênes Rompré MP, Blais AS, Urology case reports, 2014, 10.1016/j.eucr.2013.12.003
  • 2014 CUA Abstracts, Davies T, Morash C, Moore R, Black P, Kapoor A, Liu Z, Tanguay S, Mason R, Finelli A, Evans A, Kachura J, Komisarenko M, Jewett M, Bhatt J, Richard P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014
  • The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy., Guillemette C, Lévesque É, Lacombe L, Fradet Y, Caron P, Audet-Walsh É, Flageole C, Laverdière I, Endocrine-related cancer, 2014, 10.1530/erc-14-0423
  • Cystatin C for early detection of acute kidney injury after laparoscopic partial nephrectomy., Caumartin Y, Lacombe L, Dujardin T, Bergeron A, Nadeau G, Alesawi A, Urology annals, 2014, 10.4103/0974-7796.140988
  • Surgical management of stage T1 renal tumours at Canadian academic centres., Breau RH, Lattouf JB, Black PC, Drachenberg DE, Pautler SE, Kawakami J, Lacombe L, Moore RB, Rendon RA, Kapoor A, Wood L, Jewett MA, Tanguay S, Lavallée LT, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015, 10.5489/cuaj.2598
  • CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy., Wu L, Lacombe L, Fradet Y, Bollag G, West BL, Xu J, Deng G, Sung JL, Magyar C, Pouliot F, Jiang Z, Moughon D, Priceman SJ, Liu C, Schokrpur S, Escamilla J, Cancer research, 2015, 10.1158/0008-5472.can-14-0992
  • The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression., Lévesque E, Guillemette C, Lacombe L, Fradet Y, Têtu B, Simonyan D, Villeneuve L, Brisson H, Caron P, Garcia L, Hovington H, Belledant A, European urology, 2015, 10.1016/j.eururo.2015.06.054
  • CUA guidelines on the management of non-muscle invasive bladder cancer., Black P, Izawa JI, Siemens DR, Aprikian AG, Rendon R, Lacombe L, So A, Fairey A, Zlotta A, Breau RH, Kulkarni GS, Traboulsi SL, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015, 10.5489/cuaj.3320
  • Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes., Drachenberg DE, Kawakami J, Breau RH, Lacombe L, Black PC, Moore R, Rendon R, Tanguay S, Finelli A, Kapoor A, Liu Z, Saarela O, Patel P, Nayak JG, Urology, 2016, 10.1016/j.urology.2016.03.029
  • A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks., Chevalier S, Carmel M, Lacombe L, Saad F, Aprikian AG, McKercher G, Pellerin C, Biopreservation and biobanking, 2016, 10.1089/bio.2015.0113
  • Genomic hallmarks of localized, non-indolent prostate cancer., Boutros PC, Prokopec SD, Xie M, Fox NS, Masella AP, Lin X, Yousif F, Shiah YJ, Huang V, Livingstone J, Heisler LE, Yamaguchi TN, Sabelnykova VY, Fraser M, Nature, 2017, 10.1038/nature20788
  • Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer., Foley R, Fink C, Dekaban GA, Mukherjee SD, Hotte S, Favre D, Peretz Y, Landry C, Yassine-Diab B, Eady R, Salter RD, Finn OJ, Bergeron A, Major P, Scheid E, Cancer immunology research, 2016, 10.1158/2326-6066.cir-15-0189
  • 2017 CUA Abstracts, Braga L, Recker F, Sendorek D, Lalonde E, Xu J, Kwiatkowski M, Ozcelik H, Briollais L, Haider M, Pond G, Kebabdjian M, Fleshner N, Chin J, Loblaw A, Klotz L, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017
  • Erratum to "The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System" [Urol Oncol 34(11) (2016) 486.e1-486.e7]., Rendon RA, Black P, Morash C, Moore R, Kawakami J, Lacombe L, Finelli A, Jewett M, Tanguay S, Saarela O, Liu Z, Kapoor A, Mason R, Urologic oncology, 2017, 10.1016/j.urolonc.2017.01.018
  • 2017 NSAUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4896
  • Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study., Fradet V, Lacombe L, Fradet Y, Nguilé-Makao M, Ben-Zvi T, Léger C, Allaire J, Nutrition and cancer, 2017, 10.1080/01635581.2017.1367941
  • 2018 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores., Karakiewicz PI, Gleave ME, Fleshner NE, Lacombe L, Aprikian AG, Budäus L, Graefen M, Ouellet V, Tam C, Grosset AA, Zaffuto E, Latour M, Trudel D, Leyh-Bannurah SR, Pathology oncology research : POR, 2018, 10.1007/s12253-018-0408-6
  • A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples., Liang H, Cancer Genome Atlas Research Network, Weinstein JN, Zhou Z, Peng X, Li C, Chen H, Cell, 2018, 10.1016/j.cell.2018.03.027
  • An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics., Hu H, Shriver CD, Wolf DM, Omberg L, Lee AV, Levine DA, Benz CC, Kovatich AJ, Cherniack AD, Lazar AJ, Poisson LM, Hoadley KA, Lichtenberg T, Liu J, Cell, 2018, 10.1016/j.cell.2018.02.052
  • Comprehensive Characterization of Cancer Driver Genes and Mutations., Ding L, Wang Z, Cao S, Jeong KJ, Ng PK, Reardon B, Kim J, Wendl MC, Colaprico A, Weerasinghe A, Bertrand D, Sengupta S, Porta-Pardo E, Tokheim C, Bailey MH, Cell, 2018, 10.1016/j.cell.2018.02.060
  • Driver Fusions and Their Implications in the Development and Treatment of Human Cancers., Ding L, Sun SQ, Yu L, Yao L, Wyczalkowski MA, Reynolds SM, Liao WW, Cao S, Jayasinghe RG, Mutharasu G, Foltz SM, Liang WW, Gao Q, Cell reports, 2018, 10.1016/j.celrep.2018.03.050
  • A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer., Guillemette C, Chevalier S, Carmel M, Saad F, Aprikian A, Fradet Y, Simonyan D, Turcotte V, Lacombe L, Caron P, Lévesque E, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019, 10.1158/1055-9965.epi-18-1002
  • Discordance between testosterone measurement methods in castrated prostate cancer patients., Pouliot F, Guérette D, Saad F, Klotz L, Lacombe L, Guillemette C, Toren P, Fradet Y, Dubois G, Thériault B, Déry M, Lemire F, Rouleau M, Endocrine connections, 2019, 10.1530/ec-18-0476
  • Widespread and Functional RNA Circularization in Localized Prostate Cancer., He HH, Volik S, Ahmed M, Donmez N, Zhang Y, Yousif F, Wang M, Guo H, Petricca J, Hua JT, Zeng Y, Soares F, Jeon J, Livingstone J, Xu X, Huang V, Chen S, Cell, 2019, 10.1016/j.cell.2019.01.025
  • Abstraits AUQ 2018, Saad F, Rouleau M, Lemire F, Kassouf W, Mansure J, Seuntjens J, Piccirilo C, Shinde S, Ayoub M, Rompré-Brodeur A, Bolduc S, Moore K, Ramsay S, Naud E, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer., Aprikian A, Têtu B, Lacombe L, Carmel M, Saad F, Thibodeau V, Aprikian S, O'Flaherty A, McKercher G, Scarlata E, Chevalier S, Brimo F, Wissing M, BJU international, 2018, 10.1111/bju.14512
  • Genome-wide germline correlates of the epigenetic landscape of prostate cancer., Boutros PC, Livingstone J, Heisler LE, Fraser M, Huang V, O'Connor E, Bell C, Yao CQ, Ramanand SG, Shetty A, Ahmed M, Yuan J, Gusev A, Shiah YJ, Houlahan KE, Nature medicine, 2019, 10.1038/s41591-019-0579-z
  • Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression., Guillemette C, Droit A, Leclercq M, Villeneuve L, Caron P, Turcotte V, Brisson H, Rouleau M, Melo-Garcia L, Allain ÉP, Hovington H, Labriet A, Lévesque E, British journal of cancer, 2020, 10.1038/s41416-020-0749-2
  • Best practices for enhancing surgical research: a perspective from the Canadian Association of Chairs of Surgical Research, Keijzer R, Ellsmere J, Wallace C, Seely AJ, Sabbagh R, Perrault LP, Lacombe L, Fehlings MG, Cayabyab FS, Brindle M, Barralet J, Auger FA, Anderson CC, Sener A, Canadian journal of surgery. Journal canadien de chirurgie, 2019, 10.1503/cjs.012619
  • Message from our President, Romao R, Filler G, Bjazevic J, Wang Z, Berto F, Gilling P, Kaplan S, Roehrborn R, Desai M, Paterson R, So A, Goldenberg S, Elterman D, Bhojani N, Zorn K, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020
  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer., PROSPER Investigators, Noerby B, Cubero DIG, Kolinsky MP, Madziarska K, Efstathiou E, Ferreira U, Penson DF, De Giorgi U, Shore ND, Saad F, Fizazi K, Sternberg CN, The New England journal of medicine, 2020, 10.1056/nejmoa2003892
  • Achieving the "trifecta" with open versus minimally invasive partial nephrectomy., Black PC, Tanguay S, Liu Z, Jewett M, Fairey A, Lacombe L, Lavallee L, Breau RH, Moore RB, Kapoor A, Finelli A, Rendon RA, Pouliot F, Saarela O, Ghavimi S, World journal of urology, 2020, 10.1007/s00345-020-03349-y
  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer., PROfound Trial Investigators, Roubaud G, Twardowski P, Thiery-Vuillemin A, Olmos D, Agarwal N, Sartor O, Chi KN, Sandhu S, Shore N, Saad F, Fizazi K, Mateo J, Hussain M, The New England journal of medicine, 2020, 10.1056/nejmoa2022485
  • A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine., Pouliot F, Lacombe L, Fradet Y, Dujardin T, Deschênes-Rompré MP, Cloutier J, Caumartin Y, Bureau M, Bolduc S, Blouin AC, Blais AS, Paquet S, Turcotte B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6862
  • Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study, Dominique Trudel, Yves Fradet, Alain Bergeron, Louis Lacombe, Bernard Têtu, Hélène Hovington, Hélène LaRue, Mirela Birlea, Oscar Eduardo Molina, Mame-Kany Diop, Cancers, 2023, 10.3390/cancers15082217
  • Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA), Vincent Fradet, Caroline Diorio, Josée Savard, Pierre Julien, Thierry Duchesne, Yves Caumartin, Thierry Dujardin, Rabi Tiguert, Michele Lodde, Paul Toren, Louis Lacombe, Yves Fradet, Roxane Tourigny, Jean-François Pelletier, Karine Robitaille, Hanane Moussa, Nutrients, 2023, 10.3390/nu15061369
  • Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer, Chantal Guillemette, Eric Lévesque, Simone Chevalier, Michel Carmel, Fred Saad, Armen Aprikian, Louis Lacombe, Patrick Caron, Véronique Turcotte, Flora Nguyen Van Long, Michèle Rouleau, British Journal of Cancer, 2023, 10.1038/s41416-022-02040-w
  • Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors., Cordon-Cardo C, Reuter VE, Dalbagni G, Lacombe L, Lianes P, Orlow I, Cancer research, 1994
  • p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors., Massague J, Sheinfeld J, Krauter K, Mathew S, Montgomery K, Lacombe L, Polyak K, Latres E, Lee MH, Ponce-Castañeda MV, Cancer research, 1995
  • Deletion of the p16 and p15 genes in human bladder tumors., Cordon-Cardo C, Beach D, Zhang ZF, Reuter VE, Dalbagni G, Pellicer I, Serrano M, Hannon GJ, Lacombe L, Orlow I, Journal of the National Cancer Institute, 1995, 10.1093/jnci/87.20.1524
  • Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence., Cordon-Cardo C, Fradet Y, Meyer F, Rabbani F, Moore L, Lacombe L, Osman I, LaRue H, Orlow I, The American journal of pathology, 1999, 10.1016/s0002-9440(10)65105-x
  • Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors., Cordón-Cardó C, Szijan I, Zhang ZF, Delgado R, Rabbani F, Pellicer I, Lacombe L, Orlow I, International journal of cancer, 1998, 10.1002/(sici)1097-0215(19980316)75:6<819::aid-ijc1>3.0.co;2-y
  • Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome., Reuter VE, Herr HW, Fair WR, Cordon-Cardo C, Zhang ZF, Dalbagni G, Lacombe L, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, 10.1200/jco.1996.14.10.2646
  • Canadian Urological Association 62nd Annual Meeting, Quebec City, QC, June 24-27, 2006., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression., Kwon ED, Lacombe L, Fradet Y, Frank I, Bergstralh EJ, Dong H, Frigola X, Sebo TJ, Inman BA, Cancer, 2007, 10.1002/cncr.22588
  • Insomnia in men treated with radical prostatectomy for prostate cancer., Fradet Y, Lacombe L, Ivers H, Hervouet S, Simard S, Savard J, Psycho-oncology, 2005, 10.1002/pon.830
  • A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma., Zoledronic Acid Prostate Cancer Study Group, Chen B, Goas JA, Vinholes JJ, Chin JL, Lacombe L, Venner P, Tchekmedyian S, Murray R, Gleason DM, Saad F, Journal of the National Cancer Institute, 2002, 10.1093/jnci/94.19.1458
  • Can biological markers predict recurrence and progression of superficial bladder cancer?, Lacombe L, Fradet Y, Current opinion in urology, 2000, 10.1097/00042307-200009000-00013
  • Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence., Fradet Y, Meyer F, Têtu B, Lacombe L, Larue H, Allard P, Moore L, Pfister C, Clinical cancer research : an official journal of the American Association for Cancer Research, 1999
  • Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach., International Bladder Cancer Nomogram Consortium, Bochner BH, Dalbagni G, Milowsky MI, Scardino PT, Gonen M, Kattan MW, Cronin AM, Vickers AJ, Cancer, 2009, 10.1002/cncr.24615
  • An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial., C-100-12 RCC Study Group, Figlin R, Flanigan R, Isakov L, Teofilovici F, Hoos A, Zielinski H, Mulders P, Gorelov S, Gorelov AI, Lacombe L, Bukowski R, Srivastava P, Wood C, Lancet (London, England), 2008, 10.1016/s0140-6736(08)60697-2
  • Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer., Lacombe L, Fradet Y, Harel F, Larue H, Hovington H, Patry G, International journal of cancer, 2008, 10.1002/ijc.23240
  • Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer., Fradet Y, Lacombe L, Lodde M, Urology, 2010, 10.1016/j.urology.2009.12.057
  • Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy., Aprikian AG, Lacombe L, Rendon RA, Izawa J, So A, Moore R, Bochner BH, Zlotta A, Kamat AM, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010, 10.5489/cuaj.10051
  • Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2., Lacombe L, Fradet Y, Larue H, Latulippe E, Hovington H, Moore K, Lessard A, Aziz A, BJU international, 2010, 10.1111/j.1464-410x.2010.09909.x
  • 2010 NS-AUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • 2010 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer., Lévesque E, Guillemette C, Lacombe L, Fradet Y, Caron P, Douville P, Bao BY, Huang SP, Flageole C, Audet-Walsh É, Bellemare J, Nadeau G, The Journal of clinical endocrinology and metabolism, 2011, 10.1210/jc.2011-1049
  • Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy., Aprikian A, Scarlata E, Têtu B, Lacombe L, Saad F, Chevalier S, Sircar K, Brimo F, Cell and tissue banking, 2011, 10.1007/s10561-011-9284-y
  • The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy., Lévesque É, Guillemette C, Douville P, Fradet V, Fradet Y, Lacombe L, Bellemare J, Audet-Walsh É, European urology, 2011, 10.1016/j.eururo.2011.12.021
  • Northeastern Section of the American Urological Association 63(rd) Annual Meeting, New Orleans, Louisiana October 26 - 30, 2011 Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011
  • Radical cystectomyfor clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcome, , 2012
  • The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience., Rendon RA, Matsumoto E, Saad F, Lattouf JB, So A, Chin J, Tanguay S, Black P, Izawa J, Fairey A, Jacobsen N, Kapoor A, Lacombe L, Bell DG, Kassouf W, Mason RJ, Urology, 2012, 10.1016/j.urology.2011.11.058
  • Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort., Rendon RA, Drachenberg D, Lattouf JB, Cagiannos I, Fairey A, Estey E, Izawa J, Chin J, Lacombe L, Fradet Y, Aprikian AG, Bell D, Kassouf W, Power NE, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11012
  • Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience., Drachenberg D, Kassouf W, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin J, Aprikian A, Sandhu GS, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11276
  • 2012 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada., Black P, Jacobson NE, Fairey A, Fradet Y, Lacombe L, Saad F, Lattouf JB, Matsumoto E, Kapoor A, Chin J, Izawa J, Bell D, Rendon R, Kassouf W, Metcalfe M, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.12146
  • Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy., Pouliot F, Fradet Y, Fradet V, Lacombe L, Nguile Makao M, Bergeron M, Beauregard JM, Morin F, European urology focus, 2017, 10.1016/j.euf.2017.02.007
  • Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma., Izawa JI, Saad F, Fradet Y, Bell D, Lattouf JB, So A, Tanguay S, Lacombe L, Black P, Kapoor A, Fairey A, Jacobsen N, Rendon R, Chin J, Kassouf W, Williams AK, Urologic oncology, 2013, 10.1016/j.urolonc.2011.12.004
  • Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors., Boutros PC, Lacombe L, Berlin A, Murgic J, Hovington H, Orain M, Picard V, Yao CQ, Zheng J, Meng A, Haider S, Fraser M, Chua MLK, Alkallas R, Lalonde E, European urology, 2016, 10.1016/j.eururo.2016.10.013
  • Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer., Black PC, Liu Z, Saarela O, Jewett MMA, Pautler SE, Drachenberg DE, Kawakami J, Lacombe L, Breau RH, Moore RB, Kapoor A, Finelli A, Rendon RA, Forbes CM, Urologic oncology, 2016, 10.1016/j.urolonc.2016.05.034
  • Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction., Guillemette C, Fradet Y, Harvey M, Nguile-Makao M, Caron A, Hovington H, Bergeron A, Larue H, Pouliot F, Lévesque É, Fradet V, Lacombe L, Cancer prevention research (Philadelphia, Pa.), 2015, 10.1158/1940-6207.capr-15-0069
  • The Molecular Taxonomy of Primary Prostate Cancer., Cancer Genome Atlas Research Network, Cell, 2015, 10.1016/j.cell.2015.10.025
  • Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy., Fradet V, Têtu B, Fradet Y, Lacombe L, Caron A, Léger C, Nguilé-Makao M, Hovington H, Desmeules P, Diagnostic pathology, 2015, 10.1186/s13000-015-0294-0
  • Canadian guidelines for the management of small renal masses (SRM)., Finelli A, Moore R, Drachtenberg D, Pautler S, Kapoor A, Cagiannos I, Leveridge M, Kassouf W, Tanguay S, Karakiewicz PI, Lacombe L, Rendon R, Jewett MA, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015, 10.5489/cuaj.2969
  • Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis., Lebel M, Fradet Y, Lacombe L, Têtu B, Larue H, Lacombe C, Brisson H, Hovington H, Paquet ÉR, Biomarkers in medicine, 2015, 10.2217/bmm.14.115
  • The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence., Kassouf W, Bell D, Lattouf JB, So A, Chin J, Tanguay S, Black P, Izawa J, Fairey A, Jacobsen NE, Rendon R, Lacombe L, Shayegan B, Allard CB, Dason S, Kapoor A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014, 10.5489/cuaj.1985
  • Enzalutamide in metastatic prostate cancer before chemotherapy., PREVAIL Investigators, de Bono JS, Davis ID, Chowdhury S, Carles J, Bhattacharya S, Iversen P, Sternberg CN, Higano CS, Loriot Y, Rathkopf DE, Armstrong AJ, Beer TM, The New England journal of medicine, 2014, 10.1056/nejmoa1405095
  • Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration., Lacombe L, Bell D, Saad F, Lattouf JB, So A, Chin J, Tanguay S, Black P, Kapoor A, Izawa J, Fairey A, Jacobsen N, Rendon R, Kassouf W, Mauermann J, Fradet V, Urologic oncology, 2014, 10.1016/j.urolonc.2014.04.006
  • Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer., Guillemette C, Fradet Y, Têtu B, Turcotte V, Rouleau M, Caron P, Lacombe L, Laverdière I, Lévesque É, Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, 10.1158/1078-0432.ccr-13-1100
  • ABSTRAITS AUQ 2017., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4968
  • Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types., Yu L, Buonamici S, Cancer Genome Atlas Research Network, Smith PG, Zhu P, Teng T, Palacino J, Agrawal AA, Peng S, Seiler M, Cell reports, 2018, 10.1016/j.celrep.2018.01.088
  • Systematic Analysis of Splice-Site-Creating Mutations in Cancer., Ding L, Liang WW, Huang M, Varghese R, Wang F, Chai S, Climente-González H, Zhao Y, Reynolds SM, Vo NS, Wendl MC, Gao Q, Cao S, Jayasinghe RG, Cell reports, 2018, 10.1016/j.celrep.2018.03.052
  • Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas., Laird PW, Akbani R, Chatila W, Kim J, Islam M, Bowlby R, Farshidfar F, Seoane JA, Sanchez-Vega F, Cherniack AD, Schneider BG, Hinoue T, Sethi NS, Liu Y, Cancer cell, 2018, 10.1016/j.ccell.2018.03.010
  • Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas., Wang C, Donehower LA, Feng B, Akbani R, Liu Y, Greene CS, Way GP, Shen H, Fan H, Cherniack AD, Gao GF, Chambwe N, Zimmermann MT, Wang L, Knijnenburg TA, Cell reports, 2018, 10.1016/j.celrep.2018.03.076
  • Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas., Van Waes C, Cherniack AD, Shih J, Coarfa C, Creighton CJ, Byers LA, Akbani R, Walter V, Wang C, Taylor AM, Fan H, Brennan K, Liu Y, Bowlby R, Yau C, Campbell JD, Cell reports, 2018, 10.1016/j.celrep.2018.03.063
  • Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types., Liang H, Cancer Genome Atlas Research Network, Hu H, Shriver CD, Liu J, Zhang H, Li J, Yao F, Sun Y, Chen H, Chen Z, Peng X, Wang Y, Leighton JS, Ge Z, Cell reports, 2018, 10.1016/j.celrep.2018.03.047
  • Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation., Wiznerowicz M, Czerwińska P, Colaprico A, Omberg L, Gevaert O, Huelsken J, Kamińska B, Weinstein JN, Poisson L, Burzykowski T, Gentles AJ, Sokolov A, Malta TM, Cell, 2018, 10.1016/j.cell.2018.03.034
  • Oncogenic Signaling Pathways in The Cancer Genome Atlas., Schultz N, Gao Q, Daian F, Chakravarty D, Saghafinia S, Kantheti HS, Liu DL, Dimitriadoy S, La KC, Luna A, Chatila WK, Armenia J, Mina M, Sanchez-Vega F, Cell, 2018, 10.1016/j.cell.2018.03.035
  • Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics., Cancer Genome Atlas Research Network, Jayasinghe R, Cortés-Ciriano I, Tokheim C, Huang KL, Weerasinghe A, Gibbs DL, Bertrand D, Colaprico A, Thorsson V, Porta-Pardo E, Bailey MH, Ding L, Cell, 2018, 10.1016/j.cell.2018.03.033
  • Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer., Liang H, Han L, Zhang H, Chen Z, Li J, Chen H, Ge Z, Peng X, Bhavana VH, Moreno D, Jeong KJ, Tsang YH, Ng PK, Mojumdar K, Dill MT, Maglic D, Xu X, Wang Y, Cell reports, 2018, 10.1016/j.celrep.2018.10.001
  • Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients., Rätsch G, Cancer Genome Atlas Research Network, Sander C, Kohlbacher O, Stegle O, Sachsenberg T, Stark SG, Hüser M, Toussaint NC, Lehmann KV, Kahles A, Cancer cell, 2018, 10.1016/j.ccell.2018.07.001
  • Comprehensive Characterization of Cancer Driver Genes and Mutations., Ding L, Jeong KJ, Kwok-Shing Ng P, Reardon B, Kim J, Wendl MC, Colaprico A, Weerasinghe A, Bertrand D, Sengupta S, Porta-Pardo E, Tokheim C, Bailey MH, Cell, 2018, 10.1016/j.cell.2018.07.034
  • Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer., Toren P, Lacombe L, Fradet Y, Julien AS, Cyr SJ, Pelletier J, Urologic oncology, 2018, 10.1016/j.urolonc.2018.05.004
  • A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers., Akbani R, Williams C, Li X, Sumazin P, Schultz A, Rao A, Ravikumar V, Fan H, Shen H, Liu Y, Liu W, Lenoir W, Hegde AM, Kanchi RS, Korkut A, Berger AC, Cancer cell, 2018, 10.1016/j.ccell.2018.03.014
  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer., Laird PW, Wiznerowicz M, Wong CK, Bowlby R, Akbani R, Thorsson V, Cherniack AD, Taylor AM, Shen R, Drill E, Lazar AJ, Wolf DM, Hinoue T, Yau C, Hoadley KA, Cell, 2018, 10.1016/j.cell.2018.03.022
  • Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?, Toren P, Lodde M, Fradet Y, Fradet V, Lacombe L, McMartin C, Clinical genitourinary cancer, 2019, 10.1016/j.clgc.2019.07.016
  • Résumés AUQ 2021., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7674
  • Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version., Kassouf W, Rendon RA, McPherson V, Lacombe L, Izawa JI, Hanna N, French C, Fairey A, Brimo F, Breau RH, Aprikian AG, Siemens DR, Kulkarni GS, Kool R, Bhindi B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7487
  • Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text., Kassouf W, Rendon RA, McPherson V, Lacombe L, Izawa JI, Hanna N, French C, Fairey A, Brimo F, Breau RH, Aprikian AG, Siemens DR, Kulkarni GS, Kool R, Bhindi B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7367
  • Northeastern Section of the AUA 72nd Annual Meeting Abstracts, Skog J, Bjazevic J, Burton J, Razvi H, Al K, Spierling A, Bjazevic J, Li X, Kim H, Abston K, Doersch K, Samarakoon R, Higgins P, Lian F, Tang J, Donnelly L, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020
  • Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy., Guillemette C, Klotz L, Lévesque É, Lacombe L, Caron P, Ding K, Vélot L, Morin F, Toren P, Neveu B, Rouleau M, Pouliot F, The Journal of urology, 2020, 10.1097/ju.0000000000000699
  • Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation., Guillemette C, Lévesque É, Pouliot F, Lacombe L, Villeneuve L, Caron P, Turcotte V, Vaillancourt J, Drug metabolism and disposition: the biological fate of chemicals, 2019, 10.1124/dmd.119.088229
  • Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy., Herr HW, Lacombe L, Zhang ZF, Dalbagni G, British journal of urology, 1998, 10.1046/j.1464-410x.1998.00878.x
  • Cigarette smoking and chromosome 9 alterations in bladder cancer., Scher H, Reuter VE, Lacombe L, Lianes P, Dalbagni G, Connolly-Jenks C, Cao PQ, Millon TV, Lu ML, Orlow I, Cordon-Cardo C, Shu XM, Zhang ZF, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1997
  • Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients., Fradet Y, Lacombe L, Tiguert R, Harel F, Inman BA, The Journal of urology, 2003, 10.1097/01.ju.0000092500.68655.48
  • Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level., Fradet Y, Laverdière J, Lacombe L, Rigaud J, Tiguert R, The Journal of urology, 2003, 10.1097/01.ju.0000075351.51838.b3
  • Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression., Latres E, Lianes P, Ponce-Castaneda V, Lacombe L, Orlow I, Eeles R, Frye C, Liu Q, Weaver-Feldhaus J, Gruis NA, The American journal of pathology, 1995
  • Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer., Cordon-Cardo C, Zhang ZF, Dalbagni G, Fair WR, Reuter VE, Orlow I, Lacombe L, International journal of cancer, 1996, 10.1002/(sici)1097-0215(19960422)69:2<110::aid-ijc7>3.0.co;2-3
  • [Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer]., Fradet Y, Lafleur L, Gauthier J, Lacombe L, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1996
  • Blood management and radical retropubic prostatectomy: Quebec experience., Fradet Y, Lacombe L, The Canadian journal of urology, 1999
  • Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes., Fradet Y, Meyer F, Tetu B, Veilleux C, Lacombe L, Moore L, Larue H, Pfister C, International journal of cancer, 2000, 10.1002/(sici)1097-0215(20000120)89:1<100::aid-ijc16>3.0.co;2-q
  • Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer., Zoledronic Acid Prostate Cancer Study Group, Zheng M, Goas JA, Vinholes JJ, Chin JL, Lacombe L, Venner P, Tchekmedyian S, Murray R, Gleason DM, Saad F, Journal of the National Cancer Institute, 2004, 10.1093/jnci/djh141
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival., Lacombe L, Fradet Y, Douville P, Meyer F, Audet JF, Harel F, Inman BA, European urology, 2005, 10.1016/j.eururo.2004.12.015
  • Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery., Lacombe L, Fradet Y, Vigneault E, Laverdière J, Ivers H, Simard S, Savard J, Hervouet S, Journal of pain and symptom management, 2005, 10.1016/j.jpainsymman.2005.05.011
  • Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer., Fradet Y, Lacombe L, Rousseau F, Pfister C, Harel F, Bergeron A, Larue H, Decobert M, The Journal of urology, 2006, 10.1016/s0022-5347(05)00653-1
  • Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL., Tremblay RR, Fradet Y, Grégoire M, Naud A, Lacombe L, Bolduc S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007, 10.5489/cuaj.444
  • PROGRAMME SCIENTIFIQUE * SCIENTIFIC PROGRAM Association des urologues du QUébec * Qué Urological Association Congrès annuel * Annual Meeting 9 au 11 novembre 2007 * November 9-11, 2007 Hôtel Hyatt Regency Montréal Centre-Ville, Montréal PQ., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007
  • Substratification of high-risk localised prostate cancer treated by radical prostatectomy., Fradet Y, Lacombe L, Harel F, Lodde M, World journal of urology, 2008, 10.1007/s00345-008-0252-5
  • Canadian Urological Association, 63rd Annual Meeting, Edmonton, AB, June 22-25, 2008., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience., Kassouf W, Drachenberg D, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin JL, Aprikian AG, Yafi FA, BJU international, 2010, 10.1111/j.1464-410x.2010.09912.x
  • Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma., Fradet Y, Saourine A, Morin F, Friede J, Lacombe L, Lodde M, BJU international, 2010, 10.1111/j.1464-410x.2010.09212.x
  • Effect of dutasteride on the risk of prostate cancer., REDUCE Study Group, Wilson TH, Somerville MC, Tindall DJ, Teloken C, Tammela TL, Pettaway CA, Montorsi F, Marberger M, Gomella LG, Brawley OW, Bostwick DG, Andriole GL, The New England journal of medicine, 2010, 10.1056/nejmoa0908127
  • 2009 AUA-NS Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer., Fradet Y, Lacombe L, Hovington H, Harel F, LaRue H, Picard V, Bergeron A, International journal of cancer, 2009, 10.1002/ijc.24503
  • Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality., Lacombe L, Fradet Y, Tran VT, Inman BA, Cancer, 2009, 10.1002/cncr.24339
  • 2009 CUA Abstracts, Haider M, Carrier S, Casey R, Bénard F, Atala A, Hodges S, McLorie G, Bolduc S, Lamontagne P, Hamel M, Lebel S, Cloutier J, Boucher A, Ruwali A, Al Mandil M, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • 2009 CUA Abstracts, Kassouf W, Farrokhyar F, Hassouna M, Pinthus J, Goessl C, Leder B, Kupic A, Ke C, Szwedowski M, Heracek J, Tammela T, Feldman R, Egerdie B, Smith M, Saad F, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • 2009 CUA Abstracts, Luke P, Volinn W, Gittelman M, Marks L, Hill L, Hobart M, Mador D, Schultz T, Araki M, Spaliviero M, Wong C, Kassouf W, Tanguay S, Aprikian A, Yafi F, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Early detection of prostate cancer local recurrence by urinary prostate-specific antigen., Tremblay RR, Fradet Y, Lacombe L, Inman BA, Bolduc S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1074
  • Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma., Aprikian AG, Tanguay S, Wood CG, Chetner M, Chin J, Goldenberg L, Jewett M, Lacombe L, Morash C, Siemens R, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1028
  • Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?, Lacombe L, Fradet Y, Meyer F, Harel F, LaRue H, Decobert M, Cancer, 2008, 10.1002/cncr.23627
  • Abstraits AUQ 2016 Programme Scientifique - Session 1, Gebhart J, Fragoso G, Barrès V, Péant B, Ouellet V, Clairefond* S, Campeau L, Corcos J, Biardeau X, Shamout* S, Bolduc S, Moore K, Nadeau G, Ramsay* S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Podium Session 1: Prostate Cancer June 26, 2016 1050–1150, Gleave M, Ouellet V, Timilshina N, Shore N, Forer D, Wang F, Hasabou N, van Os S, Baron B, Villers A, Chowdhury S, Heidenreich A, Klotz H, Siemens D, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy., Pouliot F, Bouchard F, Rimac G, Tiguert R, Dujardin T, Lacombe L, Lemay C, Fradet Y, Caron A, Fradet V, Blouin AC, Beauregard JM, Cancer imaging : the official publication of the International Cancer Imaging Society, 2015, 10.1186/s40644-015-0038-0
  • 2015 CUA Abstracts, Kulkarni S, Power N, Punjani N, Leong H, Pautler S, Chambers A, Sener A, Brugarolas J, Tram A, Pardhan S, Sonke E, Tailly T, Mazzola C, Willie C, Power N, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015
  • Conditional survival after radical nephroureterectomy for upper tract carcinoma., Kassouf W, Kapoor A, Scherr DS, Seitz C, Remzi M, Montorsi F, Karakiewicz PI, Matsumoto K, Rouprêt M, Margulis V, Novara G, Lotan Y, Xylinas E, Ploussard G, European urology, 2014, 10.1016/j.eururo.2014.08.003
  • Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer., Bao BY, Juang SH, Lee HZ, Chang TY, Fradet Y, Lacombe L, Laverdière I, Chen LC, Chung IC, Lin VC, Huang CY, Yu CC, Guillemette C, Lévesque E, Huang SP, International journal of cancer, 2014, 10.1002/ijc.28904
  • Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway., Guillemette C, Lacombe L, Fradet Y, Rouleau M, Caron P, Audet-Walsh E, Laverdière I, Lévesque E, Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, 10.1158/1078-0432.ccr-13-2567
  • Congrés Annuel : Programme général Association des Urologues du Québec, Delouya G, Bernard G, Rousseau A, Taillon G, Morissette A, Orabi H, Bouchard *, Fred S, Thomas G, Anne-Marie M, Jennifer K, Lateef A, Melina A, Benjamin *, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014
  • Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration., Kassouf W, Kapoor A, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Jacobsen N, Estey E, Fairey A, Fradet Y, Chin JL, Izawa JI, Aprikian AG, Bachir BG, Urologic oncology, 2014, 10.1016/j.urolonc.2013.10.016
  • Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system., Kassouf W, Drachenberg D, Saad F, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Fairey A, Estey E, Rendon R, Izawa J, Chin JL, Fradet Y, Aprikian AG, Bachir BG, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013, 10.5489/cuaj.201
  • Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration., Jacobsen NE, Drachenberg D, Saad F, Lattouf JB, So A, Black P, Matsumoto E, Kapoor A, Chin J, Izawa J, Bell D, Rendon R, Tanguay S, Estey E, Kassouf W, Fairey AS, BJU international, 2012, 10.1111/j.1464-410x.2012.11474.x
  • Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression., Guillemette C, Caron P, Yu CC, Huang CY, Rouleau M, Laverdière I, Fradet Y, Bao BY, Lacombe L, Audet-Walsh É, Huang SP, Lévesque É, Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, 10.1158/1078-0432.ccr-12-2812
  • A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study., Canadian Urology Research Consortium, Chin JL, Zhang L, Kebabdjian M, McNeill IY, Klotz LH, European urology, 2012, 10.1016/j.eururo.2012.09.007
  • Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience., Izawa JI, Lattouf JB, Drachenberg D, Cagiannos I, Bell D, Rendon R, Lacombe L, Estey E, Fairey AS, Aprikian AG, Fradet Y, Chin JL, Kassouf W, Chalasani V, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011, 10.5489/cuaj.10040
  • SRD5A polymorphisms and biochemical failure after radical prostatectomy., Lévesque E, Guillemette C, Girard H, Douville P, Bao BY, Huang SP, Fradet V, Fradet Y, Lacombe L, Nadeau G, Bellemare J, Audet-Walsh E, European urology, 2011, 10.1016/j.eururo.2011.06.020
  • Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium., Parulekar WR, Tu D, Gleave M, Lacombe L, Trpkov K, Siemens DR, Jansz K, Farley A, Hersey K, Chin J, Tanguay S, Donnelly B, Kapusta L, Fleshner NE, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, 10.1200/jco.2010.32.0994
  • 2011 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011
  • Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience., Kassouf W, Drachenberg D, Saad F, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Fairey A, Estey E, Rendon R, Izawa J, Chin JL, Fradet Y, Aprikian AG, Yafi FA, BJU international, 2012, 10.1111/j.1464-410x.2012.11133.x
  • The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients., Fradet Y, Tetu B, Tiguert R, Dujardin T, Lacombe L, Fradet V, Mauermann J, European urology, 2012, 10.1016/j.eururo.2012.08.002
  • Northeastern Section of the American Urological Association 64(th) Annual Meeting, Niagara Falls, Ontario Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • Increased survival with enzalutamide in prostate cancer after chemotherapy., AFFIRM Investigators, Fléchon A, Flaig TW, Armstrong AJ, Shore ND, Chi KN, Mulders P, de Wit R, Miller K, Sternberg CN, Taplin ME, Saad F, Fizazi K, Scher HI, The New England journal of medicine, 2012, 10.1056/nejmoa1207506
  • The Immune Landscape of Cancer., Shmulevich I, Paull EO, Culhane AC, Ziv E, Plaisier CL, Eddy JA, Gao GF, Porta-Pardo E, Ou Yang TH, Bortone DS, Wolf D, Brown SD, Gibbs DL, Thorsson V, Immunity, 2018, 10.1016/j.immuni.2018.03.023
  • Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines., Cancer Genome Atlas Research Network, Wheeler D, Getz G, Hutter C, Sofia HJ, McLellan M, Ma S, Chiotti KE, Hess J, Stewart C, Kandoth C, Covington KR, Saksena G, Bailey MH, Ellrott K, Cell systems, 2018, 10.1016/j.cels.2018.03.002
  • Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer., SPARTAN Investigators, Espina BM, Trudel GC, Lopez-Gitlitz A, Uemura H, Lee JY, Mainwaring PN, Olmos D, Graff JN, Hadaschik BA, Oudard S, Chowdhury S, Saad F, Smith MR, The New England journal of medicine, 2018, 10.1056/nejmoa1715546
  • Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors., Fradet Y, Dujardin T, Tiguert R, Pouliot F, Lacombe L, Ben-Zvi T, Bergeron A, Léger C, Caron A, Lévesque J, Lodde M, Nguile-Makao M, Toren P, Fradet V, BJU international, 2017, 10.1111/bju.14041
  • Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative., Kapoor A, Jewett MAS, Liu Z, Saarela O, Pautler S, Drachenberg D, Kawakami J, Black PC, Lacombe L, Breau RH, Moore RB, Rendon R, Finelli A, Tanguay S, Bansal RK, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4264
  • A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies., Bristow RG, Hoogland AM, Verhoef EI, van Leenders GJLH, Kweldam CF, Gopalan A, Mahamud O, Bhandari V, Lalonde E, Murgic J, Pintilie M, Lo W, Chua MLK, European urology, 2017, 10.1016/j.eururo.2017.04.034
  • Quality indicators in the management of bladder cancer: A modified Delphi study., Kassouf W, Izawa J, Gotto G, Fradet Y, Fleshner N, Fairey A, Eapen L, Drachenberg D, Chung P, Chin J, Brimo F, Booth C, Blais N, Black P, Aprikian A, Khare SR, Urologic oncology, 2017, 10.1016/j.urolonc.2016.12.003
  • The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System., Rendon RA, Black P, Morash C, Moore R, Kawakami J, Lacombe L, Finelli A, Jewett M, Saarela O, Tanguay S, Liu Z, Kapoor A, Mason R, Urologic oncology, 2016, 10.1016/j.urolonc.2016.05.025
  • Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients., Dagenais F, Fradet V, Pouliot F, Lacombe L, Gagné-Loranger M, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2016, 10.1093/ejcts/ezw023
  • Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas., Greene CS, Schultz N, Ciriello G, Mina M, Cherniack AD, Sander C, Luna A, Chatila WK, La K, Armenia J, Way GP, Sanchez-Vega F, Cell reports, 2018, 10.1016/j.celrep.2018.03.046
  • Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers., Liang H, Zhao Z, Zhang H, Liu L, Birsoy K, Thomas GV, Ge Z, Li J, Du D, Mojumdar K, Tan L, Cheng F, Wang Y, Lorenzi PL, Xu X, Farshidfar F, Chen Z, Peng X, Cell reports, 2018, 10.1016/j.celrep.2018.03.077
  • Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context., Sumazin P, Sood AK, Cancer Genome Atlas Research Network, Chatterjee SS, Pan Y, Patil SL, Zorman B, Singh VP, Chen TW, Patel E, Somvanshi S, Chiu HS, Cell reports, 2018, 10.1016/j.celrep.2018.03.064
  • Pathogenic Germline Variants in 10,389 Adult Cancers., Ding L, Cherniack AD, Krassowski M, Scott AD, Oak N, Wyczalkowski MA, Reynolds S, Paczkowska M, Oh C, Wang J, Ritter DI, Wu Y, Mashl RJ, Huang KL, Cell, 2018, 10.1016/j.cell.2018.03.039
  • Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma., Black PC, Fairey AS, Fradet Y, Lacombe L, Saad F, Lattouf JB, Shayegen B, Kapoor A, Chin J, Izawa J, Bell D, Rendon RA, Kassouf W, Hamidizadeh R, Locke JA, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5377
  • The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma., Linehan WM, Godwin AK, Gibbs RA, Choueiri TK, Bottaro DP, Beroukhim R, Akbani R, Gibb EA, Bowlby R, Reznik E, Lang M, Smith CC, Fan H, De Cubas AA, Ricketts CJ, Cell reports, 2018, 10.1016/j.celrep.2018.03.075
  • The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation., Saad F, Klotz L, Karakiewicz P, Gleave M, Fleshner NE, Fazli L, Drachenberg D, Chevalier S, Bristow RG, Brimo F, Bergeron A, Aprikian A, Ouellet V, BMC urology, 2018, 10.1186/s12894-018-0392-x
  • The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma., Linehan WM, Godwin AK, Gibbs RA, Choueiri TK, Bottaro DP, Beroukhim R, Akbani R, Gibb EA, Bowlby R, Reznik E, Lang M, Smith CC, Fan H, De Cubas AA, Ricketts CJ, Cell reports, 2018, 10.1016/j.celrep.2018.06.032
  • Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada., Aprikian A, Hamel M, Lacombe L, Carmel M, Saad F, Aprikian S, McKercher G, O'Flaherty A, Chevalier S, Wissing MD, Psycho-oncology, 2019, 10.1002/pon.5031
  • A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily., Akbani R, Ravikumar V, Ling S, Roszik J, Datto M, Kwong LN, Robertson G, Berger AC, Lorenzi PL, Li X, Schultz A, Gough NR, Rao S, Kanchi RS, Zaidi S, Korkut A, Cell systems, 2018, 10.1016/j.cels.2018.08.010
  • The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer., Aprikian A, Latour M, Brimo F, Lacombe L, Carmel M, Saad F, Scarlata E, O'Flaherty A, Aprikian S, Laprise C, McKercher G, Chevalier S, Wissing M, World journal of urology, 2018, 10.1007/s00345-018-2457-6
  • Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy, Vincent Fradet, Karine Robitaille, Yves Fradet, Rabi Tiguert, Thierry Dujardin, Michele Lodde, Paul Toren, Louis Lacombe, Narcisse Singbo, Jean-François Pelletier, Samuel Fradet, Clinical Nutrition ESPEN, 2022, 10.1016/j.clnesp.2021.12.011
  • Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer., Toren P, Lacombe L, Guillemette C, Fradet Y, Dagenais F, Hovington H, D Wallis CJ, Joncas FH, Kourbanhoussen K, Asian journal of andrology, 2022, 10.4103/aja.aja_58_21
  • Double inferior vena cava systems during retroperitoneal surgery: Description of a systematic approach to a rare and challenging anatomic variant., Dagenais F, Lacombe L, Chaud GJ, Journal of vascular surgery cases and innovative techniques, 2021, 10.1016/j.jvscit.2021.12.003
  • Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series., Lodde M, Toren P, Fradet Y, Lacombe L, Lemire F, Pycha A, Comploj E, Fradet V, Fritsche HM, Tandogdu Z, Mayr R, Ladurner C, Haider M, Urologic oncology, 2019, 10.1016/j.urolonc.2019.01.017
  • Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody., Lévesque E, Fallon JK, Têtu B, Périgny M, Caron P, Simonyan D, Lacombe L, Brisson H, Hovington H, Villeneuve L, Rouleau M, Desjardins S, Labriet A, Émond JP, Drug metabolism and disposition: the biological fate of chemicals, 2019, 10.1124/dmd.119.086330
  • Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network., Canadian Prostate Cancer Biomarker Network, Gleave M, Fleshner N, Fazli L, Chevalier S, Bergeron A, Aprikian A, Latour M, Delvoye N, Barrès V, Fragoso G, Caron C, Ouellet V, Grosset AA, PLoS medicine, 2019, 10.1371/journal.pmed.1002847
  • Résumés AUQ 2019., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6229
  • The Immune Landscape of Cancer., Shmulevich I, Paull EO, Culhane AC, Ziv E, Eddy JA, Plaisier CL, Gao GF, Porta-Pardo E, Ou Yang TH, Bortone DS, Wolf D, Brown SD, Gibbs DL, Thorsson V, Immunity, 2019, 10.1016/j.immuni.2019.08.004
  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer., HERO Study Investigators, Tombal B, Walling J, Kang V, Fan X, Selby B, van Veenhuyzen DF, Bossi A, Akaza H, Tutrone R, Saltzstein DR, George DJ, Cookson MS, Saad F, Shore ND, The New England journal of medicine, 2020, 10.1056/nejmoa2004325
  • Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival., Fradet Y, Bergeron A, Lacombe L, Simonyan D, Hovington H, Brisson H, Toren P, World journal of urology, 2020, 10.1007/s00345-020-03358-x
  • Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression, Eric Lévesque, Chantal Guillemette, Simone Chevalier, Michel Carmel, Fred Saad, Armen Aprikian, David Simonyan, Véronique Turcotte, Patrick Caron, Louis Lacombe, Jean-Philippe Emond, British Journal of Cancer, 2021, 10.1038/s41416-021-01376-z
  • 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy., Pouliot F, Buteau FA, Beauregard JM, Fradet V, Toren P, Tiguert R, Lodde M, Lacombe L, Fradet Y, Dujardin T, Lavallée É, Dubois G, Goulet CR, Otis-Chapados S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7107

Contribution à l'enseignement aux cycles supérieurs